SCHEMBL20116980

SCHEMBL20116980

COC(=O)N1CC(c2noc(-c3ccc4cnn(C5COC5)c4c3)n2)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 5/20 0.40
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SCD5 Q86SK9 1/20 0.38
KIT P10721 2/20 0.37
PIK3CD O00329 3/20 0.35
HSD11B1 P28845 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
PIK3CA P42336 1/20 0.34
MTOR P42345 1/20 0.34
USP7 Q93009 1/20 0.34
SMO Q99835 1/20 0.34
IDO1 P14902 1/20 0.34
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116320 0.91 USP30 (0.45) USP30KDM4ENPC1ALDH1A1HPGD
SCHEMBL20116089 0.91 SMO (0.42) USP30KDM4ENPC1ALDH1A1HPGD
SCHEMBL20116243 0.90 KDM4E (0.42) USP30KDM4ENPC1ALDH1A1HPGD
SCHEMBL22358345 0.89 KIT (0.37) USP30KDM4ENPC1ALDH1A1HPGD
SCHEMBL20116173 0.87 USP30 (0.39) USP30KDM4ENPC1ALDH1A1HPGD
SCHEMBL20116302 0.85 PIK3CD (0.41) USP30KDM4ENPC1ALDH1A1HPGD
SCHEMBL20116244 0.85 PIK3CD (0.41) USP30KDM4ENPC1ALDH1A1HPGD
SCHEMBL22358038 0.85 PIK3CD (0.41) USP30KDM4ENPC1ALDH1A1HPGD
SCHEMBL20676513 0.84 KDM4E (0.45) USP30KDM4ENPC1ALDH1A1HPGD
SCHEMBL20676255 0.84 USP30 (0.37) USP30KDM4ENPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 USP30 3526/4885KDM4E 2853/4885NPC1 72/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 USP30 3526/4885KDM4E 2853/4885NPC1 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.